Consistent with these findings, the CBP/p300 bromodomain inhibitor I-CBP112 substantially reduces leukemic cell colony formation, induces leukemia cell differentiation, and suppresses leukemia-initiating potential of acute myeloid leukemia cells in vitro and in mouse models 96 (Table 3). This evidence concerns the gene CREBBP and acute myeloid leukemia.